Pharmaceuticals, Biotechnology and Life Sciences
SillaJen and Lee’s Pharmaceutical Holdings have said that they’ve gotten the approval from the China Food and Drug Administration (CFDA) to get a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec, the PHOCUS study.
GSK on Wednesday set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network, including investments for respiratory and HIV medicines manufacturing in the UK and strategic reviews. This includes the sale of several products and a proposal to close a UK manufacturing site.
How well cancer patients fared after chemotherapy was affected by their social interaction with other patients during treatment, according to a new study by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and the University of Oxford in the United Kingdom.
Celyad has kicked off the SHRINK trial, a third clinical trial with its lead product candidate CYAD-01 (CAR-T NKG2D), targeting metastatic colorectal patients, the company said Thursday.
Ablynx and Sanofi have made a deal for research collaboration and global exclusive licensing agreement related to Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
Cellectis S.A. and Calyxt, Inc. announced on Thursday the pricing of Calyxt’s initial public offering of 7,000,000 shares of its common stock at the initial public offering price of $8.00 per share.
The U.S. Food and Drug Administration (FDA) has cleared Neovacs’s Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate in the US its Phase IIa clinical trial already on-going in European countries.
CPhI Korea returns to Seoul COEX Convention and Exhibition Centre for its fourth edition from 22nd-24th August 2017. The show will co-locate with ICSE, P-MEC, BioPh and Health Ingredients Korea. Reflecting the global interest in the South Korean pharma market, CPhI Korea 2017 will see a 13% rise in the number of exhibitors, in addition to a more than doubling of overseas buyers since 2015.
The U.S. Food and Drug Administration on Tuesday approved Gildad’s Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir.
Novatris has reported net income of $2.9 million for the second quarter of 2017 which is a slight decrease comparing the same period last year.